Free Trial
NASDAQ:PALI

Palisade Bio Q1 2023 Earnings Report

Palisade Bio logo
$0.76 +0.04 (+5.27%)
As of 01:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Palisade Bio EPS Results

Actual EPS
-$8.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Palisade Bio Revenue Results

Actual Revenue
$0.25 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Palisade Bio Announcement Details

Quarter
Q1 2023
Time
N/A
Conference Call Date
Thursday, May 11, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Palisade Bio's Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Palisade Bio Earnings Headlines

Palisade Bio (NASDAQ:PALI) Shares Down 1.8% - What's Next?
Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.
Palisade Bio Reports Improved Quarterly Losses
See More Palisade Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Palisade Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Palisade Bio and other key companies, straight to your email.

About Palisade Bio

Palisade Bio (NASDAQ:PALI), a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

View Palisade Bio Profile

More Earnings Resources from MarketBeat